Kornimate/medical-research-clean huggingface dataset:
comparative study between intravascular ultrasonography guided and angiography-guided recanalization of coronary chronic total occlusions

Conditions: Coronary Occlusion

Summary: chronic total occlusion is defined as thrombolysis in myocardial infarction (timi) flow grade 0 with an estimated duration of at least 3 months. the interest in chronic total occlusion (cto) percutaneous coronary intervention (pci) has increased, but with failure rate up to 20%, leading to important developments in dedicated equipment and techniques. in the 2014 european guidelines on myocardial revascularization, intravascular ultrasound was recommended to guide stent implantation in selected patients, and this recommendation was a class iia/level of evidence b. in cto pci, certain angiographic features such as blunt proximal cto cap, tortuosity, heavy calcification, and lack of visibility of path in the distal vessel increase procedural difficulty


Eligibility criteria:
inclusion criteria: * patients with coronary angiography showing chronic coronary total exclusion criteria: 1. acute coronary syndrome within 3 months. 2. patients with previous coronary artery bypass graft (cabg). 3. patients with known renal insufficiency (egfr \< 60 ml/kg/m2, serum creatinine ≥ 2.5 mg/dl, or on dialysis).
influence of patient expectations with lateral epicondylalgia in applying mobilization with movement

Conditions: Tennis Elbow

Summary: lateral epicondylalgia affects people of both gender between 1 and 3% of the world population, with up to 15% in the working population reaching an average of 12 weeks off work for this reason. one of the conservative treatments that have shown effective is the mobilization with movement, whose mechanisms of action are not known. according bialosky et al., possible effects of manual therapy are based on the neurophysiological mechanisms at peripheral, spinal and supraspinal level. among the mechanisms to supraspinal level is the placebo effect, which is influenced by psychological factors such as conditioning and expectations. changing expectations to determine the influence on the treatment has been studied in healthy subjects, showing improvement with positive expectations and worsening to negative and neutral expectations. however the result of modifying the previous expectations for treatment in patients with pain has not been studied. the aim of our study is to test the influence that positive expectations have on the effectiveness of treatment with mobilization with movement in patients with lateral epicondylalgia.


Eligibility criteria:
inclusion criteria: * lateral epicondylalgia diagnosis exclusion criteria: * previous treatment with manual therapy * previous treatment with injection 6 months before * radiculopathy * bilateral symptoms * fracture

Keywords: expectations
surgical and patient reported outcomes in robotic mastectomy

Conditions: Breast Cancer

Summary: conventional nipple and/or skin-sparing mastectomy (nsm/ssm) with or without immediate reconstruction is becoming one of the mainstream surgical treatment for breast cancer and risk reducing mastectomy in recent years. while this technique provides satisfactory oncologic and aesthetic outcomes, its disadvantages include skin flap and/or nipple-areolar complex (nac) necrosis, nac malposition/distortion as well as visible scar(s) on the breast. in terms of technical aspects, nsm/ssm has its inherent challenges in view of limited incisions and thereby difficulties in dissection. since 2015, a number of institutions worldwide had adopted a new technique of nsm/ssm using robotic surgical system. institutional experiences worldwide demonstrated feasibility and safety of this technique coupled with improved patients' satisfactions. to date, there is no center in singapore or the region offering robotic nsm/ssm (r-nsm/r-ssm). the authors believe that robotic mastectomy is a feasible and safe technique that can be utilized in our institution and it provides superior aesthetic outcomes with less morbidity and higher patient satisfaction if compared to conventional nsm/ssm. the aim of this study is to conduct a single-arm prospective pilot study to investigate the safety and feasibility as well as learning curve of r-nsm/r-ssm.


Eligibility criteria:
inclusion criteria: * women aged 21-70, with invasive breast cancer, ductal carcinoma in situ (dcis), breast cancer (brca) gene or other breast cancer genetic mutation carriers or high risk female patients who are otherwise candidates for conventional nsm/ssm will be eligible for the study. all suitable patients will be offered the option of r-nsm/ r-ssm. for patients with breast cancer (invasive or dcis), selection criteria include but not limited to: 1. early breast cancer 2. tumor size less than 5 cm 3. no evidence of lymph node metastases 4. no evidence of skin or chest wall invasion. exclusion criteria: 1. extensive axillary lymph node metastasis (stage 3b or later) 2. heavy smokers (\>20 cigarettes a day) 3. high risk patient with severe and poorly controlled co-morbid conditions (include but not limited to diabetes, heart disease, renal failure or liver dysfunction) 4. poor performance status or high risk for anaesthesia (asa 3 and above) 5. inflammatory or locally advanced breast cancer (with or without chest wall or skin invasion)

Keywords: breast cancer minimally invasive breast surgery endoscopic breast surgery robotic breast surgery
study of noscapine for patients with low grade non hodgkin's lymphoma or chronic lymphocytic leukemia refractory to chemotherapy

Conditions: Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia

Summary: this study is for patients with non-hodgkin's lymphoma or chronic lymphocytic leukemia, which has failed to shrink or has returned after previous treatment with chemotherapy. the purpose of this study is to find out whether patients with these types of cancer will have their tumor shrunk after treatment with a drug called noscapine. the second purpose is to see what are the side effects of this drug. this drug is being used as an over-the-counter cough suppressor in europe and japan, but has also shown to be effective against cancer.


Eligibility criteria:
inclusion criteria: * patients with low grade nhl (follicular lymphoma, small cell lymphocytic lymphoma, marginal cell lymphoma, monocytoid b-cell lymphoma, malt lymphoma, plasmacytoid lymphocytic lymphoma) or chronic lymphocytic leukemia who have demonstrated chemotherapy resistance (have not achieved cr,cru, pr)or who have relapsed at any time following a response (cr, cru, pr) after at least one therapy regimen, including chemotherapy, rituximab, or high dose chemotherapy with stem cell rescue. * karnofsky performance status 60 % or greater. * creatinine less or equal to 2.0 mg/dl, bilirubin less or equal to 2.0 mg/dl, sgpt/sgot less or equal to 4 x upper normal range exclusion criteria: * patients with unconfirmed complete response(cru)after last treatment and who currently remain in cru. * pregnant or lactating women. * disease-specific treatment less than 1 month prior to starting this study. * cns disease. * hiv-positive patients. * other cancer, except basal cell or squamous cell cancer of the skin or carcinoma in-situ of cervix.
wind instruments' fungal contamination

Conditions: Immunologically-induced Lung Disease; Hypersensitivity Pneumonitis

Summary: on the basis of 2 cases of immunologically-induced lung disease in 2 saxophonists, the investigators supposed that wind reed instruments could be contaminated with molds. the investigators led a study on 40 musicians playing a wind reed instrument to analyze instruments' fungal contamination and its immunological and clinical consequences for musicians.


Eligibility criteria:
inclusion criteria: * must be 18 year old or more * must play a wind reed instrument (saxophone, clarinet, bassoon or oboe) one hour per week or more exclusion criteria: * refuse to sign consent

Keywords: wind instruments molds hypersensitivity pneumonitis fungal contamination of wind instruments specific antibodies against molds in musicians' sera musicians
maintenance study of certolizumab pegol (czp) in crohn's disease

Conditions: Crohn's Disease

Summary: this is a multi-centre, open-label extension study in subjects who showed clinical response to induction therapy in the treatment of subjects with active crohn's disease in the double-blind main study c87037 (nct00291668).

in the double-blind main study subjects were dosed at weeks 0, 2 and 4, with the primary outcome, clinical response, being assessed at week 6. subjects who showed clinical response at week 6 were eligible to enter this open-label extension study. the first visit in this extension study was 2 weeks after week 6, i.e., week 8. subjects in this extension study were dosed at weeks 8, 12, 16, 20 and 24, with the primary outcome, clinical response, being assessed at week 26. all week numbers quoted are relative to the start of the double-blind main study.

Eligibility criteria:
inclusion criteria: * subjects who participated in main double-blind induction study c87037 (nct00291668) and showed clinical efficacy exclusion criteria: * subjects who experienced aggravation of crohn's disease during main double-blind induction study c87037 (nct00291668) and required treatment change

Keywords: certolizumab pegol cimzia czp
phone or email reminder in increasing vaginal dilator use in patients with gynecologic cancers undergoing brachytherapy

Conditions: Cervical Cancer; Endometrial Cancer; Radiation Toxicity; Vaginal Cancer

Summary: this randomized, pilot phase i trial studies whether phone or email reminders increases vaginal dilator use in patients with endometrial, cervical, or vaginal cancers after they undergo brachytherapy. brachytherapy is a type of internal radiation which uses radioactive material placed directly into or near a tumor to kill tumor cells. a reminder program may help increase use of vaginal dilators and decrease long-term side effects following brachytherapy.

primary objectives: i. evaluate whether vaginal dilator adherence is improved with additional reminder phone calls and/or email reminder survey. secondary objectives: i. evaluate whether there are differences in the length of vaginal canal between the non-intervention and intervention groups. evaluate rates of gynecologic, urinary, and gastrointestinal toxicity. outline: patients are randomized to 1 of 3 arms. arm i: patients receive no additional reminders. arm ii: patients receive a reminder email survey every 2 weeks for 1 year after completing radiation. arm iii: patients receive a reminder email survey as in arm i and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up. after completion of study, patients are followed up at 10-14 weeks, 5-7 months, 8-10 months, 11-13 months, 15-17 months, 19-21 months, and 23-25 months post treatment.

Eligibility criteria:
inclusion criteria: * patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of their treatment * patients cannot have previously received pelvic external beam radiation or brachytherapy. patients may be enrolled while undergoing vaginal brachytherapy radiation treatment. * patients should have a life expectancy of at least 1 year * no eastern cooperative oncology group (ecog) or karnofsky performance status requirements * no organ and marrow function requirements * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * patients who have received prior pelvic external beam radiation or brachytherapy will be excluded * no restrictions regarding use of other investigational agents * no exclusion requirements due to co-morbid disease or intercurrent illness * no investigational agent, so no exclusion requirements regarding history of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent or device * no exclusion criteria relating to concomitant medications * no exclusion criteria for pregnant or nursing patients from participating in this study (of note, pregnant patients will not be treated with vaginal brachytherapy, a requirement for enrolling on this study)
hemostasis using radiofrequency ablation for track bleeding

Conditions: Bleeding

Summary: this study aims to evaluate the usefulness of hemostasis using radiofrequency ablation for track bleeding that has occurred after percutaneous biopsy of the liver.

purpose: to evaluate the usefulness of hemostasis using radiofrequency ablation for track bleeding after percutaneous liver biopsy. method: * enroll patients who continue to bleed despite conservative treatment for track bleeding that has occurred after liver biopsy. * radiofreqeuncy ablation: under monitoring vital signs and controlling pain with intravenous agents, the electrode is inserted into the bleeding focus. the bleeding focus is ablated. * hemostasis is evaluated by ultrasound (right after radiofrequency ablation), ct scan (after the radiofrequency ablation), and ultrasound (the day after radiofrequency ablation) * if hemostasis fails using radiofrequency ablation, transarterial hepatic embolization is performed immediately.

Eligibility criteria:
inclusion criteria: * ultrasound guided percutaneous liver biopsy at samsung medical center * track bleeding after biopsy * persistent track bleeding even after conservative management * consent to this study exclusion criteria: * not consent to this study * \ =80 years old * contraindication to radiofrequency ablation * radiofrequency ablation for track bleeding is not technically possible. * unstable vital signs

Keywords: liver track bleeding radiofrequency ablation
application of desferal to treat covid-19

Conditions: COVID-19

Summary: in this study, defined cases of covid-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with iv injection of deferoxamine. improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.


Eligibility criteria:
inclusion criteria: clinical diagnosis of covid-19 disease, exclusion criteria: previous history of allergy to deferoxamin, pregnancy, kidney dysfunction,

Keywords: covid-19, deferoxamine
perturbation-based balance training on trunk proprioception and balance in cerebral palsy:

Conditions: Cerebral Palsy

Summary: to investigate the effect of perturbation-based balance training on trunk proprioception and balance in hemiparetic cerebral palsy

thirty-eight patients with hemiplegic cerebral palsy will participate in this study. the patients will randomly be divided into two equal groups; the control group which received the selected physical therapy exercise program and the study group received the same exercise training program in addition to perturbation-based balance training, three times per week for three months. the evaluation methods are biodex, the pediatric balance scale, baseline digital inclinometer.

Eligibility criteria:
inclusion criteria: * - thirty-eight children hemiplegic cerebral palsy * age will range as (8:10) years old * spastic hemiplegic cerebral palsy * normal body mass index ranged from 1sd to -2sdaccording to bmi-for age z score charts include an age and sex- specific bmi for children (who, 2007). * gross motor function classification system: level i\&ii exclusion criteria: * • difficulty to communicate or to understand program instructions * any other neurological deficits or orthopaedic abnormalities, * secondary musculoskeletal complication * vestibular problems * any mental impairment
pilot study of sodium bicarbonate in generally healthy people with low bicarbonate

Conditions: Chronic Kidney Disease

Summary: the goal of this pilot study is to determine whether oral sodium bicarbonate can raise low serum bicarbonate concentration in people without chronic kidney disease (ckd). participants will take sodium bicarbonate for six weeks, followed by a four week washout period.

ckd affects 25 million americans and the risks of cardiovascular morbidity, hospitalizations, and death are substantially higher for people with ckd. furthermore, 6% of the total medicare budget is spent on 600,000 people with end-stage renal disease. thus, ckd is highly prevalent, associates with poor outcomes, and is a tremendous financial burden to society. apart from treating hypertension and diabetes, there are no therapies that prevent ckd. however, results from two studies have found that low serum bicarbonate levels increase risk of developing ckd, which suggests that normalizing low serum bicarbonate may prevent ckd. one way to raise low serum bicarbonate is by taking sodium bicarbonate. whether sodium bicarbonate, which is commonly prescribed to raise low serum bicarbonate in people with ckd, can raise low bicarbonate in people without ckd is uncertain because the reason bicarbonate is low in people without ckd is unclear. this is because low bicarbonate by itself cannot distinguish whether the acid-base abnormality is primary metabolic acidosis or respiratory alkalosis. the former process is readily corrected with alkali. however, the administration of alkali in the latter situation may not raise bicarbonate concentration. therefore, the purpose of this pilot study is to determine whether oral sodium bicarbonate can raise low serum bicarbonate in people without renal disease. the study is a single-arm open label study of 15 individuals without ckd with low serum bicarbonate concentration. the study duration is 10 weeks. after completing the baseline visit, participants will take oral sodium bicarbonate (initial dose level: 0.3 milliequivalents per kilogram per day (meq/kg/d) for 6 weeks (on-treatment period), followed by a 4 week off-treatment period. serum concentrations of sodium bicarbonate will be tested during the treatment period, at the end of the on-treatment period (week 6) and at the end of the off-treatment period (week 10).

Eligibility criteria:
inclusion criteria: * estimated glomerular filtration rate (egfr) ≥ 60 ml/min/1.73m2 * urinary albumin/creatinine ratio \< 30 mg/gm * serum bicarbonate ≤ 23 meq/l (average of the two most recent measurements within the past year) * age ≥ 50 years exclusion criteria: * blood pressure ≥ 160/100 mm hg * serum potassium \< 3.5 meq/l * new york heart association class 3 or 4 heart failure symptoms * chronic oxygen therapy * chronic obstructive pulmonary disease requiring daily bronchodilator or prednisone therapy * weight ≥ 160 kg * use of sodium bicarbonate, sodium citrate, potassium citrate, or potassium bicarbonate within the previous two weeks.

Keywords: low serum bicarbonate level sodium bicarbonate
rivaroxaban in patients with atrial fibrillation undergoing pci

Conditions: Non-valvular Atrial Fibrillation; Acute Coronary Syndrome; Percutaneous Coronary Intervention; Antithrombotic Therapy

Summary: this study evaluates the antithrombotic therapy in patients suffering from atrial fibrillation after stent implantation in germany. patients prescribed with the novel oral anticoagulant rivaroxaban will be followed up over 14 months for their adherence to the medication schedule and for complications that occurred after index pci.

patients suffering from non-valvular atrial fibrillation and presenting with an acute coronary syndrome require special attention with regard to antithrombotic therapy. current guidelines recommend use of oral anticoagulation for almost all of these patients, the optimal antithrombotic strategy, however, has still to be defined. as with the use of any antithrombotic drug, clinicians need to balance the risks of ischemic stroke and thromboembolism, recurrent cardiac ischemia and/or stent thrombosis, and bleeding and haemorrhagic stroke. a recently published randomized clinical trial (pioneer af) compared the combination of a novel oral anticoagulant (noac; rivaroxaban) plus dual anti-platelet therapy (dapt) with standard therapy consisting of vitamine k inhibitor plus dapt. patients treated with rivaroxaban showed less incidence of bleedings, whereas ischemic complications, death or stroke were equal in the groups compared. the riva-pci registry aims at providing an overview of the current antithrombotic treatment regimen in germany in real life. moreover, for patients receiving rivaroxaban as part of their medication follow-up data with regard to their adherence to antithrombotic medication as well as complications over an interval of 14 months after index procedure will be evaluated.

Eligibility criteria:
inclusion criteria: * age ≥18 years and capable of giving written informed consent * known or newly diagnosed non-valvular atrial fibrillation * pci with stent implantation during index hospital stay * written informed consent for participation in observational study (incl. telephone follow-up) * not simultaneously participating in any randomized trial exclusion criteria: * none

Keywords: non-valvular af acs pci noac rivaroxaban
randomized study on effects of uniportal vats versus triportal vats

Conditions: Lung Cancer

Summary: for the treatment of stage i-ii nsclc, two mini-invasive techniques are mostly utilized: uni-portal and three-portal vats. in the uniportal approach, the injury on a single intercostal space could determine a lower level of pain than the three-portal approach, allowing a better postoperative course. few studies in literature compare these techniques, and most of them are retrospective. the main purpose of this randomized study is to compare uni-portal vats with three-portal vats, in terms of postoperative pain. secondary objectives of the study are valutations of: * respiratory and functional capacity between the two groups * operative time * number of resected lymphnodes * intra and postoperative complications, such as conversions to open surgery, amount of bleeding, prolonged air leaks, surgical site infections, pulmonary complications.

randomized cohort clinical trial, prospectic, monocentric. procedure of randomization: the day before the operation, with the "random allocation rule" technique arm 1: pulmonary lobectomy and lymphoadenectomy with uni-portal vats approach arm 2: pulmonary lobectomy and lymphoadenectomy with three-portal vats approach misurations total analgesic consumption, normalized to morphine milligrams, recorded in the 7 days following the operation. the choice of cumulative analgesic consumption as parameter of primary outcome is because pain valuation with vas is significantly affected by individual variability. secondary outcomes: measure of postoperative pain with nrs at 2,6,12,24 hours and at 2,3,4,5,30 days from sugery. a pain score will be assigned to each patient after the total amount of nrs. respiratory function will be valuated with spirometry after 7 and 30 days from surgery, and compared with pre-operative tests. all intraoperative parameters will be compared between the two groups: operative time (skin to skin), proportion of conversions to open surgery, number of resected lymphnodes, amount of bleeding. postoperative complications will be analyzed: rate of prolonged air leaks, surgical site infections, cardiac rythhm disfunctions, pulmonary complications, post-thoracotomy syndrome, as well as lenght of stay at the hospital.

Eligibility criteria:
inclusion criteria: * patients with ct1-2n0-1m0 nsclc, maximum diameter 5cm * asa (american society of anestesiology) score 1-2-3 exclusion criteria: * n2-n3 disease * induction chemotherapy * thoracic wall infiltration * previous thoracic surgery * important pleural adhesions * severe copd, asthma, interstitial lung disease - liver, kidney or cardiac failure * clotting disorders * analgesic allergy * sublobar resection, sleeve lobectomy, pneumonectomy * chronic analgesic, oppioids or cortisonic use * absence of informed consent

Keywords: vats pulmonary lobectomy uniportal postoperative pain thoracic surgery